

CARDIOTEC MEDICAL LIMITED
ABRIDGED UNAUDITED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

CARDIOTEC MEDICAL LIMITED
CONTENTS

	Page
Director's Responsibilities Statement	3
Balance Sheet	4
Statement of Changes in Equity	5
Notes to the Financial Statements	6 - 8

CARDIOTEC MEDICAL LIMITED
DIRECTOR'S RESPONSIBILITIES STATEMENT
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

The director made the following statement in respect of the unaudited financial statements:

"General responsibilities

The director is responsible for preparing the Director's Report and the financial statements in accordance with applicable Irish law and regulations.

Irish company law requires the director to prepare financial statements for each financial year. Under that law, the director has elected to prepare the financial statements in accordance with the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard, issued by the Financial Reporting Council. Under company law, the director must not approve the financial statements unless they is satisfied that they give a true and fair view of the assets, liabilities and financial position of the company as at the financial year end date and of the profit or loss of the company for the financial year and otherwise comply with the Companies Act 2014.

In preparing these financial statements, the director is required to:

- select suitable accounting policies for the company financial statements and then apply them consistently;
- make judgements and accounting estimates that are reasonable and prudent;
- state whether the financial statements have been prepared in accordance with applicable accounting standards, identify those standards, and note the effect and the reasons for any material departure from those standards; and
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the company will continue in business.

The director is responsible for ensuring that the company keeps or causes to be kept adequate accounting records which correctly explain and record the transactions of the company, enable at any time the assets, liabilities, financial position and profit or loss of the company to be determined with reasonable accuracy, enable them to ensure that the financial statements and Director's Report comply with the Companies Act 2014. They is also responsible for safeguarding the assets of the company and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

Director's declaration on unaudited financial statements

In relation to the financial statements which comprise the Balance Sheet, the Statement of Changes in Equity and the related notes:

The director approves these financial statements and confirms that they is responsible for them, including selecting the appropriate accounting policies, applying them consistently and making, on a reasonable and prudent basis, the judgements underlying them. They have been prepared on the going concern basis on the grounds that the company will continue in business.

The director confirms that they has made available to Strata Financial, all the company's accounting records and provided all the information, books and documents necessary for the compilation of the financial statements.

The director confirms that to the best of their knowledge and belief, the accounting records reflect all the transactions of the company for the financial year ended 31 December 2025."

Signed on behalf of the board



Philip Strickland
Director

3 March 2026

CARDIOTEC MEDICAL LIMITED
BALANCE SHEET
AS AT 31 DECEMBER 2025

	Notes	2025 €	2024 €
Current Assets			
Stocks	6	22,367	19,218
Debtors	7	314,425	53,052
Cash and cash equivalents		84,695	189,575
		421,487	261,845
Creditors: amounts falling due within one year	8	(279,055)	(115,043)
Net Current Assets		142,432	146,802
Total Assets less Current Liabilities		142,432	146,802
Capital and Reserves			
Called up share capital presented as equity		100	100
Retained earnings		142,332	146,702
Equity attributable to owners of the company		142,432	146,802

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland", applying Section 1A of that Standard.

I as Director of Cardiotec Medical Limited, state that -

- (a) the company is availing itself of the exemption provided for by Chapter 15 of Part 6 of the Companies Act 2014,
- (b) the company is availing itself of the exemption on the grounds that the conditions specified in section 358 are satisfied,
- (c) the shareholders of the company have not served a notice on the company under section 334(1) in accordance with section 334(2),
- (d) I acknowledge the company's obligations under the Companies Act 2014, to keep adequate accounting records and prepare financial statements which give a true and fair view of the assets, liabilities and financial position of the company at the end of its financial year and of its profit or loss for such a financial year and to otherwise comply with the provisions of the Companies Act 2014 relating to financial statements so far as they are applicable to the company,
- (e) the company has relied on the specified exemption contained in section 352 Companies Act 2014. The company has done so on the grounds that the company is entitled to the benefit of that exemption as a small company and the abridged financial statements have been properly prepared in accordance with section 353 Companies Act 2014 and the small companies' regime.

Approved by the board on 3 March 2026 and signed on its behalf by:



Philip Strickland
Director

CARDIOTEC MEDICAL LIMITED
STATEMENT OF CHANGES IN EQUITY
AS AT 31 DECEMBER 2025

	Called up share capital €	Retained earnings €	Total €
At 1 January 2024	100	162,248	162,348
Loss for the financial year	-	(15,546)	(15,546)
At 31 December 2024	100	146,702	146,802
Loss for the financial year	-	(4,370)	(4,370)
At 31 December 2025	100	142,332	142,432

CARDIOTEC MEDICAL LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

1. GENERAL INFORMATION

Cardiotec Medical Limited is a company limited by shares incorporated and registered in Ireland. The registered number of the company is 617382. The registered office of the company is Unit 10 Hills Industrial Estate, Lower Lucan Road, Lucan, Co. Dublin, K78 E224, Ireland which is also the principal place of business of the company. The principal activity of Cardiotec Medical Limited is the retail sale of medical and orthopaedic goods in specialised stores. The financial statements have been presented in Euro (€) which is also the functional currency of the company.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in dealing with items which are considered material in relation to the company financial statements.

Statement of compliance

The financial statements of the company for the financial year ended 31 December 2025 have been prepared in accordance with the provisions of FRS 102 Section 1A (Small Entities) and the Companies Act 2014.

Basis of preparation

The financial statements have been prepared on the going concern basis and in accordance with the historical cost convention except for certain properties and financial instruments that are measured at revalued amounts or fair values, as explained in the accounting policies below. Historical cost is generally based on the fair value of the consideration given in exchange for assets. The financial reporting framework that has been applied in their preparation is the Companies Act 2014 and FRS 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" Section 1A, issued by the Financial Reporting Council.

The company qualifies as a small company as defined by section 280A of the Companies Act 2014 in respect of the financial year, and has applied the rules of the 'Small Companies Regime' in accordance with section 280C of the Companies Act 2014 and Section 1A of FRS 102.

Turnover

Turnover is measured as the fair value of the consideration received or receivable, exclusive of trade discounts and value added tax. Turnover is recognised to the extent that it is probable that the economic benefits will flow to the company and the turnover can be reliably measured.

Retained earnings

The director have decided to disclose the changes in retained earnings in the Profit and Loss Account.

Stocks

Stocks are valued at the lower of cost and net realisable value. Stocks are determined on a first-in first-out basis. Cost comprises expenditure incurred in the normal course of business in bringing stocks to their present location and condition. Full provision is made for obsolete and slow moving items. Net realisable value comprises actual or estimated selling price (net of trade discounts) less all further costs to completion or to be incurred in marketing and selling.

Trade and other debtors

Trade and other debtors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest method less impairment losses for bad and doubtful debts except where the effect of discounting would be immaterial. In such cases the receivables are stated at cost less impairment losses for bad and doubtful debts.

Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and in hand, demand deposits with banks and other short-term highly liquid investments with original maturities of three months or less and bank overdrafts. In the Balance Sheet bank overdrafts are shown within Creditors.

Trade and other creditors

Trade and other creditors are initially recognised at fair value and thereafter stated at amortised cost using the effective interest rate method, unless the effect of discounting would be immaterial, in which case they are stated at cost.

CARDIOTEC MEDICAL LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

Taxation and deferred taxation

Current tax represents the amount expected to be paid or recovered in respect of taxable profits for the financial year and is calculated using the tax rates and laws that have been enacted or substantially enacted at the Balance Sheet date.

Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the balance sheet date where transactions or events have occurred at that date that will result in an obligation to pay more tax in the future, or a right to pay less tax in the future. Timing differences are temporary differences between the company's taxable profits and its results as stated in the financial statements.

Deferred tax is measured on an undiscounted basis at the tax rates that are anticipated to apply in the periods in which the timing differences are expected to reverse, based on tax rates and laws that have been enacted or substantively enacted by the Balance Sheet date.

Foreign currencies

Monetary assets and liabilities denominated in foreign currencies are translated at the rates of exchange ruling at the Balance Sheet date. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated at the rates of exchange ruling at the date of the transaction. Non-monetary items that are measured at fair value in a foreign currency are translated using the exchange rates at the date when the fair value was determined. The resulting exchange differences are dealt with in the Profit and Loss Account.

Ordinary share capital

The ordinary share capital of the company is presented as equity.

3. OPERATING LOSS	2025	2024
	€	€
Operating loss is stated after charging:		
Loss on foreign currencies	8,034	9,544
	<u> </u>	<u> </u>
4. INTEREST PAYABLE AND SIMILAR EXPENSES	2025	2024
	€	€
Interest	-	(42)
	<u> </u>	<u> </u>
5. EMPLOYEES	2025	2024
	Number	Number
Director	1	1
	<u> </u>	<u> </u>
6. STOCKS	2025	2024
	€	€
Finished goods and goods for resale	22,367	19,218
	<u> </u>	<u> </u>
7. DEBTORS	2025	2024
	€	€
Trade debtors	314,425	47,641
Taxation	-	5,411
	<u> </u>	<u> </u>
	314,425	53,052
	<u> </u>	<u> </u>

CARDIOTEC MEDICAL LIMITED
NOTES TO THE ABRIDGED FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2025

8. CREDITORS	2025	2024
Amounts falling due within one year	€	€
Trade creditors	167,197	83,470
Taxation	107,826	27,776
Director's current account (Note 11)	37	37
Accruals	3,995	3,760
	279,055	115,043
	279,055	115,043
 9. INCOME STATEMENT		
	2025	2024
	€	€
At 1 January 2025	146,702	162,248
Loss for the financial year	(4,370)	(15,546)
	142,332	146,702
	142,332	146,702
 10. CAPITAL COMMITMENTS		
The company had no material capital commitments at the financial year-ended 31 December 2025.		
 11. DIRECTOR'S REMUNERATION AND TRANSACTIONS	2025	2024
	€	€
Remuneration	70,000	38,000
Pension contributions	100,670	57,968
	170,670	95,968
	170,670	95,968
The following amounts are repayable to the director:		
	2025	2024
	€	€
Philip Strickland	37	37
	37	37
	37	37
 12. RELATED PARTY TRANSACTIONS		
During the year the company purchased goods and services from Medivent Limited to the value of €74,601. (2024 €72,278). These parties share common directors.		
 13. POST-BALANCE SHEET EVENTS		
There have been no significant events affecting the company since the financial year-end.		
 14. APPROVAL OF FINANCIAL STATEMENTS		
The financial statements were approved and authorised for issue by the board on 3 March 2026.		